Kennedy D W, Hoffer M E, Holliday M
Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania School of Medicine, Philadelphia 19104.
Otolaryngol Head Neck Surg. 1993 Sep;109(3 Pt 1):461-7. doi: 10.1177/019459989310900312.
A 2-year prospective double-blind study was performed to evaluate the role of etidronate disodium for the treatment of progressive hearing loss in patients with otosclerosis. A pulsed dosage regimen was used during the 2-year period and the patients were followed up with otologic and audiometric examinations. Although statistically significant differences were not achieved between the study and control groups, the study did reveal a trend toward stabilization or improvement in air conduction thresholds in some frequencies (1000 and 4000 Hz) and in bone conduction thresholds at other frequencies (500, 1000, and 2000 Hz). The incidence of adverse side effects was similar in the treatment and control groups. Although no definite conclusions can be drawn from this pilot study, the findings provide encouragement for performing a larger and longer-term study.
进行了一项为期2年的前瞻性双盲研究,以评估依替膦酸二钠治疗耳硬化症患者进行性听力损失的作用。在这2年期间采用脉冲给药方案,并对患者进行耳科和听力检查随访。虽然研究组和对照组之间未达到统计学上的显著差异,但该研究确实显示出在某些频率(1000和4000赫兹)的气导阈值以及其他频率(500、1000和2000赫兹)的骨导阈值有稳定或改善的趋势。治疗组和对照组的不良反应发生率相似。虽然从这项初步研究中无法得出明确结论,但这些发现为开展更大规模和更长期的研究提供了鼓励。